Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14(4):535–62.

Article  PubMed  Google Scholar 

Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):280–92.

Article  PubMed  Google Scholar 

Porsteinsson AP, Isaacson RS, Knox S, Sabbagh MN, Rubino I. Diagnosis of Early Alzheimer’s Disease: Clinical Practice in 2021. J Prev Alzheimers Dis. 2021;8(3):371–86.

CAS  PubMed  Google Scholar 

Aisen PS, Jimenez-Maggiora GA, Rafii MS, Walter S, Raman R. Early-stage Alzheimer disease: getting trial-ready. Nat Rev Neurol. 2022;18(7):389–99.

Article  PubMed  PubMed Central  Google Scholar 

Rasmussen J, Langerman H. Alzheimer’s Disease - Why We Need Early Diagnosis. Degener Neurol Neuro. 2019;9:123–30.

Google Scholar 

van der Flier WM, de Vugt ME, Smets EMA, Blom M, Teunissen CE. Towards a future where Alzheimer’s disease pathology is stopped before the onset of dementia. Nature Aging. 2023;3(5):494–505.

Article  PubMed  Google Scholar 

Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, et al. Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease. J Prev Alzheimers Dis. 2022;9(2):197–210.

CAS  PubMed  Google Scholar 

van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in Early Alzheimer’s Disease. N Engl J Med. 2023;388(1):9–21.

Article  PubMed  Google Scholar 

Sims JR, Zimmer JA, Evans CD, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512–27. https://doi.org/10.1001/jama.2023.13239.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Whelan R, Barbey FM, Cominetti MR, Gillan CM, Rosicka AM. Developments in scalable strategies for detecting early markers of cognitive decline. Transl Psychiatry. 2022;12(1):473.

Article  PubMed  PubMed Central  Google Scholar 

Klyucherev TO, Olszewski P, Shalimova AA, Chubarev VN, Tarasov VV, Attwood MM, et al. Advances in the development of new biomarkers for Alzheimer’s disease. Transl Neurodegener. 2022;11(1):25.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Teunissen CE, Verberk IMW, Thijssen EH, Vermunt L, Hansson O, Zetterberg H, et al. Blood-based biomarkers for Alzheimer’s disease: towards clinical implementation. Lancet Neurol. 2022;21(1):66–77.

Article  CAS  PubMed  Google Scholar 

Hansson O, Edelmayer RM, Boxer AL, Carrillo MC, Mielke MM, Rabinovici GD, et al. The Alzheimer’s Association appropriate use recommendations for blood biomarkers in Alzheimer’s disease. Alzheimers Dement. 2022;18(12):2669–86.

Article  CAS  PubMed  Google Scholar 

Alber J, Goldfarb D, Thompson LI, Arthur E, Hernandez K, Cheng D, et al. Developing retinal biomarkers for the earliest stages of Alzheimer’s disease: What we know, what we don’t, and how to move forward. Alzheimers Dement. 2020;16(1):229–43.

Article  PubMed  Google Scholar 

Snyder PJ, Alber J, Alt C, Bain LJ, Bouma BE, Bouwman FH, et al. Retinal imaging in Alzheimer’s and neurodegenerative diseases. Alzheimers & Dementia. 2021;17(1):103–11.

Article  CAS  Google Scholar 

Alber J, Arthur E, Sinoff S, DeBuc DC, Chew EY, Douquette L, et al. A recommended “minimum data set” framework for SD-OCT retinal image acquisition and analysis from the Atlas of Retinal Imaging in Alzheimer’s Study (ARIAS). Alzh Dement-Dadm. 2020;12(1):e12119.

Google Scholar 

Swenor BK, Ehrlich JR. Ageing and vision loss: looking to the future. Lancet Glob Health. 2021;9(4):e385–6.

Article  CAS  PubMed  Google Scholar 

Varma R, Vajaranant TS, Burkemper B, Wu S, Torres M, Hsu C, et al. Visual Impairment and Blindness in Adults in the United States: Demographic and Geographic Variations From 2015 to 2050. JAMA Ophthalmol. 2016;134(7):802–9.

Article  PubMed  PubMed Central  Google Scholar 

Flaxman AD, Wittenborn JS, Robalik T, Gulia R, Gerzoff RB, Lundeen EA, et al. Prevalence of Visual Acuity Loss or Blindness in the US: A Bayesian Meta-analysis. JAMA Ophthalmology. 2021;139(7):717–23.

Article  PubMed  PubMed Central  Google Scholar 

Jack CR. Biomarker Modeling of Alzheimer ’ s Disease. 2014;80(6):1347–58.

Google Scholar 

Jack CR, Holtzman DM. Biomarker modeling of Alzheimer’s disease. Neuron. 2013;80(6):1347–58.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207–16.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol. 2010;9(1):119–28.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Altomare D, de Wilde A, Ossenkoppele R, Pelkmans W, Bouwman F, Groot C, et al. Applying the ATN scheme in a memory clinic population: The ABIDE project. Neurology. 2019;93(17):e1635–46.

Article  PubMed  Google Scholar 

Baker JE, Lim YY, Pietrzak RH, Hassenstab J, Snyder PJ, Masters CL, Maruff P. Cognitive impairment and decline in cognitively normal older adults with high amyloid-β: A meta-analysis. Alzheimer’s & dementia (Amsterdam, Netherlands). 2017;6:108–21.

Article  Google Scholar 

Caselli RJ, Dueck AC, Osborne D, Sabbagh MN, Connor DJ, Ahern GL, et al. Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. N Engl J Med. 2009;361(3):255–63.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu Y, Phu J, Aung HL, Hesam-Shariati N, Keay L, Tully PJ, et al. Frequency of coexistent eye diseases and cognitive impairment or dementia: a systematic review and meta-analysis. Eye. 2023;37(15):3128–36.

Article  PubMed  PubMed Central  Google Scholar 

Kuzma E, Littlejohns TJ, Khawaja AP, Llewellyn DJ, Ukoumunne OC, Thiem U. Visual Impairment, Eye Diseases, and Dementia Risk: A Systematic Review and Meta-Analysis. J Alzheimers Dis. 2021;83(3):1073–87.

Article  CAS  PubMed  Google Scholar 

Littlejohns TJ, Hayat S, Luben R, Brayne C, Conroy M, Foster PJ, et al. Visual Impairment and Risk of Dementia in 2 Population-Based Prospective Cohorts: UK Biobank and EPIC-Norfolk. J Gerontol A Biol Sci Med Sci. 2022;77(4):697–704.

Article  CAS  PubMed  Google Scholar 

Paik JS, Ha M, Jung YH, Kim GH, Han KD, Kim HS, et al. Low vision and the risk of dementia: a nationwide population-based cohort study. Sci Rep. 2020;10(1):9109.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nagarajan N, Assi L, Varadaraj V, Motaghi M, Sun Y, Couser E, et al. Vision impairment and cognitive decline among older adults: a systematic review. BMJ Open. 2022;12(1):e047929.

Article  PubMed  PubMed Central  Google Scholar 

Hwang PH, Longstreth WT Jr, Brenowitz WD, Thielke SM, Lopez OL, Francis CE, et al. Dual sensory impairment in older adults and risk of dementia from the GEM Study. Alzheimers Dement (Amst). 2020;12(1):e12054.

PubMed